J&J catches its menin rivals
The company has caught up with Syndax and overtaken Kura in the first-line menin inhibitor race.
Kyowa joins GSK in Tim-3
Meanwhile, Tango tries again in PRMT5.
Kura’s Komet fizzles
The company heralds a pivotal win with its menin inhibitor, but investors want to see data.
The month ahead: January’s upcoming events
Investors will hope for a JP Morgan buying spree, while readouts could come from Kura, Allogene and MacroGenics.
Kyowa buys into menin, but it's not Syndax's
Syndax scored the first menin approval, but Kura is first with a licensing deal.
